Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 340.16 USD -1.52% Market Closed
Market Cap: 183.2B USD

Intrinsic Value

The intrinsic value of one AMGN stock under the Base Case scenario is 303.51 USD. Compared to the current market price of 340.16 USD, Amgen Inc is Overvalued by 11%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AMGN Intrinsic Value
303.51 USD
Overvaluation 11%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Amgen Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about AMGN?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is AMGN valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Amgen Inc.

Explain Valuation
Compare AMGN to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

A potential wave of biosimilar competition for flagship products such as Enbrel and Otezla threatens to erode market share and pressure margins as payers increasingly turn to lower-cost alternatives.

Amgen’s development pipeline faces uncertainties, with notable delays or setbacks in key therapeutic areas like oncology and cardiovascular, raising concerns about insufficient near-term replacement for maturing products.

Rising scrutiny of high drug prices in the U.S. and abroad could constrain Amgen’s ability to maintain premium pricing for its biologics, potentially dampening revenue and profit growth.

Bull Theses

Amgen’s recent acquisitions, including its purchase of ChemoCentryx, expand its footprint in high-value rare disease and autoimmune segments, potentially offsetting sales declines from mature blockbuster drugs.

Strong commercial execution and a diversified portfolio of biologics, including Prolia and Repatha, position Amgen to leverage its robust global distribution infrastructure and maintain stable revenue streams.

Significant free cash flow generation and disciplined capital allocation enable continued investment in innovative drug candidates and support shareholder returns through dividends and buybacks, strengthening investor confidence.

Show More Less
How do you feel about AMGN?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Amgen Inc

Current Assets 27.9B
Cash & Short-Term Investments 9.4B
Receivables 8.5B
Other Current Assets 10B
Non-Current Assets 62.3B
PP&E 7.2B
Intangibles 41.8B
Other Non-Current Assets 13.2B
Current Liabilities 21.8B
Accounts Payable 19.6B
Other Current Liabilities 2.2B
Non-Current Liabilities 58.7B
Long-Term Debt 52.4B
Other Non-Current Liabilities 6.3B
Efficiency

Free Cash Flow Analysis
Amgen Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Amgen Inc

Revenue
36B USD
Cost of Revenue
-10.1B USD
Gross Profit
25.9B USD
Operating Expenses
-13.8B USD
Operating Income
12.1B USD
Other Expenses
-5.1B USD
Net Income
7B USD
Fundamental Scores

AMGN Profitability Score
Profitability Due Diligence

Amgen Inc's profitability score is 64/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROE
Exceptional ROE
Exceptional Operating Margin
Exceptional Gross Margin
64/100
Profitability
Score

Amgen Inc's profitability score is 64/100. The higher the profitability score, the more profitable the company is.

AMGN Solvency Score
Solvency Due Diligence

Amgen Inc's solvency score is 28/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Average Altman Z-Score
Positive Net Debt
28/100
Solvency
Score

Amgen Inc's solvency score is 28/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AMGN Price Targets Summary
Amgen Inc

Wall Street analysts forecast AMGN stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AMGN is 327.38 USD with a low forecast of 181.8 USD and a high forecast of 420 USD.

Lowest
Price Target
181.8 USD
47% Downside
Average
Price Target
327.38 USD
4% Downside
Highest
Price Target
420 USD
23% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for AMGN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

AMGN Insider Trading
Buy and sell transactions by insiders

AMGN News

Other Videos
What is the Intrinsic Value of one AMGN stock?

The intrinsic value of one AMGN stock under the Base Case scenario is 303.51 USD.

Is AMGN stock undervalued or overvalued?

Compared to the current market price of 340.16 USD, Amgen Inc is Overvalued by 11%.

Back to Top